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Transgenicuseful tools that facilitate targeted single copy knock-in (KI) at the hypoxanthine
guanine phosphoribosyl transferase 1 (Hprt1) locus. We employed ﬁne scale mapping to delineate the precise
breakpoint location at the Hprt1b-m3 locus allowing allele speciﬁc PCR assays to be established. Our suite of
tools contains four targeting expression vectors and a complementing series of embryonic stem cell lines.
Two of these vectors encode enhanced green ﬂuorescent protein (EGFP) driven by the human
cytomegalovirus immediate-early enhancer/modiﬁed chicken beta-actin (CAG) promoter, whereas the other
two permit ﬂexible combinations of a chosen promoter combined with a reporter and/or gene of choice. We
have validated our tools as part of the Pleiades Promoter Project (http://www.pleiades.org), with the
generation of brain-speciﬁc EGFP positive germline mouse strains.
© 2008 Elsevier Inc. All rights reserved.IntroductionThe transgenic mouse continues to play an important role in the
study of human development, physiology, and disease. We have
designed a collection of tools that facilitate single-copy knock-in at the
selectable hypoxanthine guanine phosphoribosyl transferase 1
(Hprt1) locus in mouse embryonic stem cells (ESCs). Consistent levels
of transgene expression and little to no phenotypic variability in
mouse strains derived from knock-ins at this deﬁned insertion site
produce uniformity of results and do not require examination of large
numbers of mouse strains [1]. This is in contrast to random insertion
experiments, where the initial knock-in step is simpler, but often leads
to undesirable effects such as uncontrolled copy number, variablee and Therapeutics, Child and
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n).
Therapeutics, Child and Family
University of British Columbia,
l rights reserved.expression levels, variability in phenotype, and insertional mutagen-
esis, necessitating the characterization of multiple strains of mice [2–
5]. The Hprt1 tool set we describe here facilitates targeted insertion
such that the difﬁculty of the knock-in is less of a consideration in
experimental design.
The HPRT1 enzyme is important in the salvage of purines for
biosynthesis of nucleotides, providing an alternate to the de novo
nucleotide synthesis pathways. Speciﬁcally, HPRT1 catalyzes the
conversion of hypoxanthine and guanine to the mononucleotides
IMP and GMP, respectively [6–9]. The Hprt1 locus, located on the X
Chromosome (Chr), is 44 kb in size and comprised of 9 exons [9].
HPRT1 is ubiquitously expressed in all tissues, and the Hprt1 locus is
relatively neutral as a transgene docking site because the locus has
minimal inﬂuence on transgene expression when driven by an
exogenous promoter [1,2,10]. Although functional deletion of HPRT1
in humans leads to Lesch–Nyhan syndrome (reviewed in [11]), only a
mild phenotype is observed in the mouse knockout [12–14], but in the
knock-in (KI) mouse the sequences typically introduced into the locus
complements the gene and Hprt1 is expressed. Thus, the locus is
useful in mice for single-copy gene targeting. A spontaneous deletion
occurring at the mouse Hprt1 locus, Hprt1b-m3 [15], has been well
characterized in embryonic stem cells and mice (E14TG2a, HM-1 and
Fig. 1. Novel plasmid vectors facilitate single copy insertion at the Hprt1 locus.
pEMS1306/pEMS1307 (promoterless (−CAG)), and pEMS1157/pEMS1277 (+CAG)
vectors containing Hprt1 homology regions (5′ Hom, 3′ Hom, solid grey arrows),
HPRT1 complementary sequence (HPRT1-CS, slashed arrow), containing the human
HPRT1 promoter (hP), human exon 1 (h1), and mouse exon 2 (m2) and 3 (m3), multiple
cloning site (MCS), minimal FRT (MFRT) and full FRT (FFRT) WT and F5 mutant sites,
SV40 polyadenylation (SV40 polyA) site, nuclear localization signal (NLS), tetracysteine
motif (Tetcys-M), ampicillin resistance (AmpR, checkered arrows), EGFP reporter (black
arrow), and I-SceI linearization site.
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much larger bacterial artiﬁcial chromosome (BAC) constructs [10].
This spontaneous deletion removes two essential exons from the 5′
end of the Hprt1 locus. Complementation of the locus by homologous
recombination with KI vectors containing the two deleted exons [16]
allows positive selection of recombinants. A large majority of selected
clones are typically correctly targeted [19–21]. This is an important
advantage overmore standard positive–negative selection systems for
targeting. The ability to select, both positively, with HAT (hypox-
anthine, aminopterin, thymidine), and negatively, with 6-thioguanine,
for targeting events at this locus establishes Hprt1 as a valuable tool
for transgenesis both in vitro, and in vivo [9,17]. The X Chr location of
the Hprt1 locus can be a concern given that single copy insertions in
females are subject to random X-inactivation, which may result in
mosaic expression of the transgene [10]. However, the X Chr location
of theHprt1 locus can also be beneﬁcial as all the daughters of a carrier
father will have the transgene, thus reducing the need for genotyping.
We have advanced the existing Hprt1 targeting and expression
system [16] and developed more sophisticated tools, including
expression vectors, embryonic stem cells (ESCs), and PCR assays, for
mouse genome modiﬁcation at this locus. A new vector, pEMS1306,
has been designed to facilitate the single copy delivery of either a
promoter driving EGFP and/or a gene of interest to the Hprt1 locus. In
our current application, different promoter constructs of interest are
inserted into the multiple cloning site and used to drive expression of
a downstream enhanced green ﬂuorescent protein (EGFP) reporter.
We have also developed two series of new hybrid ESCs that
show high germline competence. These ESCs are hemizygous for the
Hprt1b-m3 spontaneous deletion and heterozygous or wild-type (WT)
for Gt(ROSA)26Sortm1Sor, which serves as a Cre reporter and historical
marker. As with the traditional E14TG2a ESC line, these ESCs have
proven useful for making new transgenic strains by conventional
microinjection. An additional beneﬁt of these new ESC lines is the
ability to use the co-culture technique to produce germline competent
chimeras, which is not permissible using E14TG2a [21]. These vectors
and ESCs have also enabled us to derive a new strain of mice carrying
the human cytomegalovirus immediate-early enhancer/modiﬁed
chicken beta-actin (CAG) promoter driving the EGFP tetracysteine
reporter from pEMS1306, knocked in to the Hprt1b-m3 locus. Moreover
we have deﬁned the exact boundaries of the spontaneous breakpoint
at Hprt1b-m3 carried by E14TG2a and the mouse strain B6.129P2-
Hprt1b-m3, enabling us to design new speciﬁc PCR assays for this and
the Hprt1 WT alleles. We have also designed primers that are speciﬁc
for the HPRT1 complementary sequence (HPRT1-CS: human-to-
mouse) at the Hprt1 locus only after it is complemented by a targeting
event.
Results
Multi-featured vectors enable and expand functionality of docking at the
Hprt1 locus
Two targeting vectors, pEMS1306 and pEMS1307 (Fig. 1), were
developed to facilitate single copy insertion of transgenes targeted to
the Hprt1 locus. The backbone sequence of both vectors contains the
homologous sequence required to target the Hprt1 locus in mouse
ESCs that contain the Hprt1b-m3 deleted allele. Proper integration of
the vectors complements the structure and function of the Hprt1 gene
and allows positive selection of the recombinants. Our vectors encode
a multiple cloning site (MCS) containing a total of ﬁve restriction sites,
including the eight-cutters, FseI and AscI. These two rare restriction
sites are less likely to be found within the promoter to be cloned
allowing greater opportunity for directional cloning of promoter
constructs with a wider range of sequence variability. The chosen
promoter drives expression of a reporter gene that is an EGFP/
tetracysteine motif fusion. The tetracysteine tag allows alternativedetection by arsenical ligands [22]. In addition, the tetracysteine-
tagged EGFP marker is ﬂanked by 5′ mutant (F5), and 3′ wild-type
(WT) FRT sites, allowing Flp-recombination mediated cassette
exchange (RMCE) [23] of the EGFP reporter with a preferred gene of
choice. The pEMS1306 and pEMS1307 targeting vectors differ only in
that pEMS1306 containsminimal FRT (MFRT), 34 bp, sites compared to
the full FRT (FFRT), 48 bp, version in pEMS1307 [24]. This modiﬁcation
was driven by the successful use of FFRTs for RMCE in mouse ESCs
[23,25,26]. There is also an upstream Kozak consensus sequence to
increase the translation efﬁciency of the reporter gene in eukaryotic
cells in addition to three copies of a nuclear localization signal (NLS)
for increased translocation efﬁciency of the protein into the nucleus of
the cells. An SV40 polyadenylation signal directs proper processing of
the mRNA 3′ end in both of these constructs.
Two additional constructs, pEMS1277, and pEM1277, were gener-
ated using the ubiquitously expressed human cytomegalovirus
immediate-early enhancer/modiﬁed chicken beta-actin (CAG) promo-
ter to test the functionality of the EGFP reporter in the pEMS1306 and
pEMS1307 vector backbones. Four constructs, pEMS1306, pEMS1157,
pEMS1307, and pEMS1277 were electroporated into mEMS1204 ESCs,
and all of the constructs generated colonies upon HAT selection
indicating proper homologous recombination and complementation of
the Hprt1b-m3 locus. Colonies were picked for screening by PCR to
conﬁrm the presence of the transgene immediately upstream of the
Hprt1 locus. The high frequency (90–95%) of correct homologous
recombination events we observe at the Hprt1b-m3 locus is similar to
previously published data [10,16,18–20].
Enabling the utilization of the Hprt1b-m3 spontaneous deletion locus by
ﬁne scale mapping
Although the sequences ﬂanking the breakpoint in the E14TG2a
cell line (and subclones) and Hprt1b-m3 mice are characterized [27],
the exact breakpoint has never been deﬁned.We used direct sequence
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the 36 kb deletion [10], to determine the precise location of the
breakpoint, which lies 415 bp after the 3′ end of Exon 2 (Fig. 2A). The
ﬁne scale mapping of the locus allowed us to design new, more
deﬁned primer sets that distinguish between the Hprt1b-m3 (b-m3)
and the Hprt1 WT mouse alleles (Fig. 2B). We have also designed
primers that are speciﬁc to the HPRT1-complementary sequence
(HPRT1-CS; human-to-mouse) in our Hprt1 targeting vector back-
bones (along with the corresponding mouse-speciﬁc assay) (Table 2).
This HPRT1-CS assay only ampliﬁes a ‘complemented’ product when
the Hprt1 locus is complemented by a homologous targeting event.
These assays consistently and clearly amplify in our ESCs, knock-in
(KI) clones, and germline mice. The presence of both the Hprt1 WT
and HPRT1-CS alleles, but not the b-m3 and ‘WT@ CS’ alleles, in our KI
clones indicates that the HPRT1-CS has corrected the deletion and
integrated correctly at the Hprt1 locus (Fig. 2C). However, it is
important to note that the Hprt1 WT assay at the breakpoint cannot
distinguish between WT mouse Hprt1 and a complemented Hprt1
after a targeting event, whereas our HPRT1-CS assay can, and neither
of these assays can determine copy number, nor can they distinguish
between a combination of a correct targeting and a random integrant
elsewhere in the genome, or a scrambled targeting event at the Hprt1
locus.Fig. 2. Delineation of the precise location of the breakpoint at the Hprt1b-m3 locus. (A) Compa
the Hprt1 locus. Arrowheads signify breakpoint location. Using the newly deﬁned breakpoin
box denotes oEMS2240 (b-m3 forward primer); Black box denotes oEMS2238 (WT forward
primer). (B) New Hprt1 assay distinguishes between the WT and b-m3 alleles in mice an
homozygous (Homo) mouse shows only the b-m3 allele; (3) C57BL/6J mouse shows only the
the b-m3 allele. L, 100 bp ladder. (C) The HPRT1-CS (CS) assay in combination with the Hprt1
ESC clone DNA shows only the Hprt1WTallele and not the b-m3 allele indicating a complem
indicating the presence of the human-to-mouse DNA from the vector backbone in the mEMHigh germline competency obtained with new B6129F1 hybrid Hprt1b-m3
ESC lines
Thirty-eight new hybrid Hprt1b-m3 ESC lines were established
utilizing the B6.129P2-Hprt1b-m3 (B6-Hprt1b-m3) and B6.129S4-Gt
(ROSA)26Sortm1Sor/J (129-ROSA26) mouse strains, and six of these
(mEMS1202, mEMS1205, and mEMS1217 (Gt(ROSA)26Sor+/+) and
mEMS1204, mEMS1213, and mEMS1218 (Gt(ROSA)26Sortm1Sor/+))
were chosen for initial characterization. mEMS1204 (B6129F1-Gt
(ROSA)26Sortm1Sor/+, Hprt1b-m3/Y), was expanded to compare its
germline potential with the current standard Hprt1 deﬁcient cell
line, E14TG2a. Both cell lines were microinjected and generated
chimeras, which were then bred to allow for direct comparison of
germline competency. Microinjection of mEMS1204 into 98 B6(Cg)-
Tyrc-2J/J (B6-Alb) blastocysts demonstrated a high level of sex-reversal
in the resultant chimeras (24 male: 4 female, Pb0.001 (Fig. 3A)).
Twenty-one of the male chimeras (8.5–65% coat color chimerism)
were bred to B6-Alb females,17 (81%) of them producing an average of
6 germline pups/litter (Figs. 3B and 4), and 13 of these 17 male
chimeras gave 100% germline pups (average 6 pups/litter). In all cases,
germline progeny were identiﬁed by the presence of the Tyr+
(tyrosinase WT) coat color allele in combination with the dominant
Aw (white bellied agouti) or recessive a (nonagouti) coat color allelesrison of the wild-type (WT) and Hprt1b-m3 (b-m3) sequences deﬁnes the break point at
t sequence, more speciﬁc PCR assays for the WT and b-m3 alleles were designed. White
primer); Grey box denotes oEMS2236 (located on antisense strand) (common reverse
d ESCs. (1) Hprt1b-m3/+ heterozygous (Het) mouse shows both alleles; (2) Hprt1b-m3
WTallele; (4) E14TG2a ESCs show only the b-m3 allele; (5) mEMS1204 ESCs show only
WT assay indicates proper homologous recombination at the Hprt1 locus. mEMS1600
ented Hprt1 locus. The ‘WT @ CS’ allele does not amplify whereas the CS allele ampliﬁes
S1600 ESC clone DNA. L, 100 bp ladder.
Fig. 3. New hybrid ESC line, mEMS1204, is superior to E14TG2a. (A) Injection of
mEMS1204 ESCs results in signiﬁcantly more chimeras born/total blastocysts injected
compared to E14TG2a (solid line, ⁎⁎Pb0.005; E14TG2a: 57 chimeras/636 blastocysts,
mEMS1204: 28 chimeras/98 blastocysts). Of the total chimeras born/total blastocysts
injected, mEMS1204 ESC injections also produced signiﬁcantly more male chimeras
(dashed line, ⁎⁎⁎Pb0.001). mEMS1204 ESCs also show extensive sex reversal in
chimeric offspring compared to E14TG2a (dotted lines, mEMS1204, ⁎⁎⁎Pb0.001;
E14TG2a, ⁎Pb0.05). Data shown is normalized to 100 blastocysts. White = female
chimeras, black = male chimeras. (B) Male chimeras derived from mEMS1204
demonstrate a signiﬁcantly higher rate of fertility and germline competence than
those derived from E14TG2a. None of the mEMS1204 male chimeras were sterile
compared to 26.5% sterility observed in E14TG2a chimeras (⁎Pb0.05; dark grey bars)
and over 60% of mEMS1204 chimeras demonstrated 100% germline competence
compared to only 14.7% of E14TG2a chimeras (⁎⁎⁎Pb0.001; white bars). Both cells lines
generated males that were fertile but non-germline (black bars; 41% E14TG2a vs.19%
mEMS1204), and males that were less than 100% germline (light grey bars; 17.6%
E14TG2a vs. 19% mEMS1204).
Fig. 4. Germline competent chimera derived from mEMS1204 ESCs. Chimeras bred to
B6-Alb females can produce 3 colors of N1 progeny. N1 germline progeny will carry the
Tyr+ (tyrosinase wild type) with Aw (white bellied agouti) or a (nonagouti) alleles
making them appear brown with a cream belly, or black, respectively. Non-germline
progeny will be homozygous for the Tyrc-2J (albino 2 Jackson) allele making them
appear white.
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respectively. Non-germline progeny, homozygous for the Tyrc-2J
(albino 2 Jackson) coat color allele of the donor B6-Alb strain,
appeared white. Microinjection of the two other established B6129F1-
Gt(ROSA)26Sortm1Sor/+ ESC lines (mEMS1213 and mEMS1218) gave
similar results (data not shown). Importantly, we have designed new
PCR assay for the Tyrc-2J allele, facilitating its removal in subsequent
generations of progeny derived from these new ESCs without solely
relying on breeding to achieve full congenic status on the B6
background.
Injection of E14TG2a into 636 blastocysts from C57BL/6J (B6) and
B6-Alb, demonstrated a very low level of sex-reversal (36 male: 21
female, Pb0.05 (Fig. 3A)). Thirty-four of the male chimeras (2–85%
coat color chimerism) were bred to B6 or B6-Alb females, 11 (32%)
of them producing an average of 3 germline pups/litter (Fig. 3B)
and 5 of these 11 male chimeras gave 100% germline pups
(average 6 pups/litter). Germline pups from B6 matings were
identiﬁed by the presence of the dominant Aw, resulting in progeny
that appeared brown with a cream belly, whereas non-germline
progeny, homozygous for the recessive a coat color allele of the donor
B6 strain, appeared black. Germline progeny from B6-Alb matings
were identiﬁed by the combination of Aw and Tyrc-ch (chinchilla) coatcolor alleles, resulting in progeny that appear golden, whereas non-
germline progeny, homozygous for the Tyrc-2J coat color allele of the
donor B6-Alb strain, appeared white.
It is well known that hybrid ESC lines have the potential to
successfully produce ESC-derived mice through co-culture/comple-
mentation [28–30], whereas inbred ESC lines such as E14TG2a lack
this ability [21]. We tested the diploid co-culture ability of untargeted
and multiple knock-in mEMS1204 ESC lines and have successfully
derived germline competent mouse strains using the method of Lee
et al. [30] (data not shown).
Widespread expression in mEMS1600 strain validates new tools for
Hprt1 targeting
To conﬁrm the effectiveness of our new tools, we processed the
brains of post-natal day 14 (P14) germline N3 (third generation
backcross to C57BL/6J) mice from our B6.129P2-Hprt1tm2(CAG-EGFPm1600)/
Ems (mEMS1600) CAG strain and examined them for EGFP expression
(Fig. 5). We compared the expression of mEMS1600 to that of the B6-
(CAG-EGFP)1Osb strain, a random insertion multiple copy CAG strain
(M. Okabe, Genome Information Research Center, Research Institute
for Microbial Diseases, Osaka University, Osaka, Japan, March 26,
2008, pers. comm.). The EGFP reporter can be observed under
confocal ﬂuorescence with illumination using FITC (ﬂuorescein
isothiocyanate) excitation/emission ﬁlter sets (Bio-Rad, Hercules, CA).
As predicted, all brain regions examined in the mEMS1600 strain
showed widespread expression of EGFP under the control of the CAG
promoter (Fig. 5A). Strikingly, the EGL (external granular layer) in the
mEMS1600 mice showed very high EGFP expression, a unique
expression pattern for this CAG strain. Additionally, the mEMS1600
strain does not show extensive expression of EGFP in blood vessels
that is seen in the B6-(CAG-EGFP)1Osb strain (Fig. 5C). The observed
ﬂuorescence intensity seen in mEMS1600 brains is substantially less
than that seen in age matched B6-(CAG-EGFP)1Osb brains. These
intensity differences are likely due to the fact that the mEMS1600
CAG-EGFP expression construct is present in the genome as a single
copy, in contrast with the random insertion multiple copy transgene
in the B6-(CAG-EGFP)1Osb CAG strain.
Discussion
We have designed a set of molecular tools which facilitate single
copy, site-speciﬁc knock-in (KI) targeting to the Hprt1 locus. The new
pEMS1306 and pEMS1307 vectors in conjunction with the new
Fig. 5.Widespread expression of EGFP driven by CAG validates the new Hprt1 tool set. Confocal images from the cerebellum of (A) mEMS1600 (CAG driving EGFP) P14 germline N3,
demonstrates direct EGFP ﬂuorescence, with high EGFP expression seen in the EGL, and very little in the blood vessels; (B) an age matched C57BL/6J demonstrates the level of
background green ﬂuorescence in the green channel in absence of EGFP expression; and (C) an age matched C57BL/6-Tg(CAG-EGFP)1Osb heterozygote (random insertion, multi-
copy) demonstrates EGFP expression driven by a similar CAG promoter in the context of a traditional transgenic animal, showing high levels of EGFP expression throughout the brain,
especially in the blood vessels. (A) and (B) images were captured using 100% laser intensity and optimal gain settings and (C) was captured at 30% the laser intensity and 50–60% the
gain. The inset in (C) shows this section captured at 100% laser intensity and optimal gain settings. Scale bar=100 μm.
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expressing Hprt1 KI mice which express the EGFP reporter gene. We
are currently using this new Hprt1 tool set as part of the Pleiades
Promoter Project to test 250 humanMiniPromoter KI constructs at the
Hprt1 locus (http://www.pleiades.org). These MiniPromoters are from
a set of 70 genes that are expressed in spatially and temporally deﬁned
areas of the brain, which have an associationwith human disease. This
new Hprt1 tool set has proven to be highly efﬁcient, straightforward,
and has advanced the existing technologies.
Our purpose in deriving single-copy KI is to recapitulate the
physiological levels of gene expression, but we are currently
examining ways in which we will be able to increase the levels of
EGFP expression in our vectors. One method for increasing the
expression of our EGFP reporter would be the addition of an intron
[31,32] into the vector backbone, thus splicing would occur regardless
of the promoter insert. This method has been shown to increase the
transcriptional efﬁciency of reporter genes 10 to 100 fold [33,34]. The
use of insulators in expression vectors is another possible method. For
example, Ciavatta et al. [35] have shown that using DNA insulators
during targeting to the Hprt1 locus enhanced expression of the
targeted transgene, showing promise for the increased effectiveness
of our Hprt1 tool set.
It is well known that hybrid ESC lines are capable of producing
viable embryos using diploid and tetraploid complementation/
aggregation technologies [21,28,29,36] whereas existing inbred ESC
lines (e.g. E14TG2a) are not [21]. This phenomenon is attributed to
the fact that deleterious homozygous genes and/or modiﬁers of gene
expression are made heterozygous, the phenomenon of ‘hybrid
vigor’. We have successfully tested the ability of mEMS1204, a new
hybrid ESC line, to derive chimeras through diploid aggregation, and
predict this cell line will be able to do the same with tetraploid
methodologies.
Traditionally, the host blastocyst for microinjection is C57BL/6 (B6)
[37] as the majority of standard ESC lines are derived from 129
substrains. These 129-derived ESC lines carry the dominant A (agouti)
coat color allele at the nonagouti (a) locus and will generate germline
progeny that appear brown, andnon-germlineprogeny, derived fromthe
host blastocyst, which appear black. Since mEMS1204 ESCs are
heterozygous (Aw/a) at the non-agouti locus, using the traditional B6
(a/a) host blastocysts would result in half the germline progeny and all
the non-germline progeny being homozygous for the non-agouti (a/a)
coat color allele, and therefore black. This would necessitate all black
progeny being genotyped for the transgene, which would be time
consuming. These current ESC series are therefore limited to
injections using the albino strain B6(Cg)-Tyrc-2J/J (B6-Alb) as the
blastocyst donor. Resultant germline progeny can then be easilyidentiﬁed as they will carry the wild-type allele at the tyrosinase
(Tyr+) locus, in combination with the Aw or a alleles, making them
appear brown with a cream belly or black, respectively, whereas
non-germline progeny will be homozygous for the albino allele at
Tyr (Tyrc-2J) and appear white. We are currently developing new
hybrid ESC lines which will utilize the agouti C57BL/6J-Aw-J/J (JAX
Stock#000051; B6-Ag) mouse strain, which is homozygous for the
dominant Aw-J (white bellied agouti Jackson) coat color allele. ESCs
derived from a cross between the B6-Ag and 129S1/SvImJ strains
will carry the agouti alleles from both parental strains (Aw-J/Aw) and
will therefore be able to make use of both the B6-Alb (a/a, Tyrc-2J/
Tyrc-2J) and classic C57BL/6 (a/a, Tyr+/Tyr+) strains as host blas-
tocysts. When crossed back to the host strain(s), all the germline
progeny generated will be heterozygous for one of the dominant A
alleles and the Tyr+ allele from the ESCs, and appear brown with a
cream belly, whereas non-germline progeny will be black (a/a, Tyr+/
Tyr+ from B6) or white (a/a, Tyrc-2J/Tyrc-2J from B6-Alb).
We have shown that our newly developed Hprt1 tool set is a
valuable addition to the existing technologies for integration of
transgenes into the genome. Our tools facilitate site-speciﬁc, single-
copy knock-in of an EGFP reporter driven by CAG but also have the
ﬂexibility to examine other promoters or genes of interest. Our tools
provide a straightforward, efﬁcient alternative to random insertion
transgenics.
Materials and methods
Targeting vectors and constructs
Construction of the two targeting vectors pEMS1306 and
pEMS1307 (Fig. 1) made use of the pJDH8A/246b I-SceI plasmid [10]
as the source of Hprt1 homology regions required for docking at the
mouse Hprt1 locus. Prior to the use of the pJDH8A/246b I-SceI plasmid
[10] the 3′ loxP site was removed completely and the 5′ loxP site was
mutated by removal of the middle 14 bp (5′-ATGTATGCTATACG-3′)
sequence using a site-directed mutation approach. Primers loxP-
mut_P1_L_Kpn1 and loxPmut_P1_R were used to generate PCR
product 1 (Table 1). Primers loxPmut_P2_L and loxPmut_P2_R_EcoRI
generated PCR product 2. Primer loxPmut_P1_L_Kpn1 is tailed with a
KpnI restriction end, primer loxPmut_P2_EcoR1 is tailed with an EcoRI
end, and primer loxPmut_P1_R is tailed with a 20 bp sequence
homologous to the ﬁrst 20 bp of PCR product 2. PCR products 1 and 2
were used as template in a third PCR reaction to produce the ﬁnal
fusion PCR product 3, a 3397 bp segment with KpnI and EcoRI
restriction ends, a single mutated loxP site, and no second loxP site.
The original pJDH8A/246b I-SceI was digested with KpnI and EcoRI to
Table 1
Mutational and ampliﬁcation primer sequences and assays
Primer name Primer sequence (5′–3′) Assay
loxPmut_P1_L_Kpn1 GGTACCTCATTTGTTCAAGACCAG pJDH8A/246b I-SceI loxP mutation
loxPmut_P1_R ATTAAGGGTTCCGGATCCTA pJDH8A/246b I-SceI loxP mutation
loxPmut_P2_L TAGGATCCGGAACCCTTAATATAACTAAGTTATTAGGTCCCTC pJDH8A/246b I-SceI loxP mutation
loxPmut_P2_R_EcoRI GAATTCATTAAGGGTTATTGAATATGA pJDH8A/246b I-SceI loxP mutation
IV_CAG_F GAGCTCTGCAGGCGTTACATAACT PCR amplify CAG from pDRIVE-CAG, SacI tailed
IV_CAG_R ACGCGTGGTGGAAGCTACTGTACA PCR amplify CAG from pDRIVE-CAG, MluI tailed
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product 3. The correct assembly for the modiﬁcation was veriﬁed by
sequencing, and the new plasmid was called pJDH8A_modlox.
Two different segments of DNA each containing their respective
vector elements for pEMS1306 and pEMS1307 were directly
synthesized at Geneart (Germany) and designed with ﬂanking
EcoRI restriction ends for subcloning into the EcoRI linearized
pJDH8A_modlox plasmid. The pEMS1306 segment is 1150 bp and
includes a multiple cloning site (MCS) that contains SacI, AvrII, MluI,
and two octamer restriction enzyme sites, FseI and AscI. These
restriction site sequences can then be incorporated into PCR primers
for subcloning fragments into our vectors. The restriction sites were
screened against the vector to ensure that they were unique. A Kozak
consensus translation initiation site and enhanced green ﬂuorescent
protein (EGFP) sequence from pEGFP-N3 (Clontech/BD Biosciences,
Mississauga, ON) were added downstream, and the EGFP stop codon
was mutated by altering TAA to TTA. Immediately downstream of
EGFP is an in-frame 36 bp tetracysteine residue sequence (5′-
FLNCCPGCCMEP-3′) [22] followed by three copies of an in-frame
nuclear localization sequence (NLS), obtained from pACGFP1-Nuc
(Clontech, Mountain View, CA). A TAA stop codon was added to the 3′
end of the NLS resulting in an EGFP-tetracysteine-NLS fusion protein
when expressed. On the 5′ end of the EGFP-tetracysteine-NLS
sequence is a 34 bp F5 mutant FRT sequence and on the 3′ end is a
34 bp wild-type (WT) FRT sequence. An SV40 early mRNA
polyadenylation signal from pEGFP-N3 was included downstream of
the FRT ﬂanked EGFP-tetracysteine-NLS fusion protein. The
pEMS1307 segment was identical to pEMS1306 with the exception
that one additional 14 bp (5′-GAAGTTCCTATTCC-3′) segment was
added to the 5′ ends of both FRT sites creating full FRT (FFRT) sites
compared to the minimal FRT (MFRT) sites featured in pEMS1306.
Once the synthesized pEMS1306 and pEMS1307 segments were
available, each EcoRI tailed segment was subcloned into an EcoRI
linearized pJDH8A_modlox plasmid. Each vector was sequence
veriﬁed using a transposon mediated shotgun approach [38].
The human cytomegalovirus immediate-early enhancer/modiﬁed
chicken beta-actin (CAG) promoter was directionally cloned into the
SacI/MluI digested pEMS1306 and pEMS1307 targeting vectors
generating the pEMS1157 and pEMS1277 constructs, respectively.
The 1627 bp CAG product was generated from the vector pDRIVE-CAG
(Invivogen, San Diego, CA) by PCR ampliﬁcation using the SacI and
MluI tailed PCR primers IV_CAG_F and IV_CAG_R, respectively.
Importantly, all our vectors contain a unique I-SceI restriction site
for linearization prior to electroporation into ESCs.
Animals and husbandry
B6.129P2-Hprt1b-m3/J, abbreviated here as B6-Hprt1b-m3 (JAX
Stock#002171), B6.129S4-Gt(ROSA)26Sortm1Sor/J, abbreviated here as
129-ROSA26 (JAX Stock#003474), B6(Cg)-Tyrc-2J/J, abbreviated here as
B6-Alb (JAX Stock#000058), C57BL/6-Tg(CAG-EGFP)1Osb/J, abbreviated
here as B6-(CAG-EGFP)1Osb (JAX Stock#003291), C57BL/6J-Aw-J/J,
abbreviated here as B6-Ag (JAX Stock#000051), C57BL/6J, abbreviated
here as B6 (JAX Stock#000664) and 129S1/SvImJ, abbreviated here
as 129 (JAX Stock#002448) mice were obtained from The JacksonLaboratory, Bar Harbor, ME, and CD-1(ICR) (Charles River Stock#022)
mice were obtained from Charles River, Wilmington, MA and
maintained at the Centre for Molecular Medicine and Therapeutics
(CMMT). All mice were maintained in the pathogen-free CMMT animal
facility on a 6 am–6 pm light cycle, 20±2 °C with 50±5% relative
humidity and had food and water ad libitum. All procedures involving
animals were in accordance with the Canadian Council on Animal Care
(CCAC) and UBC Animal Care Committee (ACC) (Protocol# A05-1258
and A05-1748).
Derivation of mEMS1204 embryonic stem cells
Blastocysts were obtained from natural mating of B6-Hprt1b-m3
females to 129-ROSA26males at 3.5 dpc (days post-coital). Blastocysts
were ﬂushed from uterine horns as per Hogan et al. [37], cultured in
EmbryoMax® KSOM with 1/2 Amino Acids, Glucose and Phenol Red
(Cat#MR-121, Millipore/Chemicon, Temecula, CA) for 3–5 h, and then
transferred onto mitomycin C (mitC; Cat#M4287, Sigma-Aldrich,
Oakville, ON) mitotically inactivated B6-Hprt1b-m3, B6129F1, or 129
mouse embryonic feeders (MEFs) derived from 13.5-dpc embryos [39]
in 96-well plates containing KSR-ESC media (Knockout™ D-MEM
(Cat#10829-018, Invitrogen, Burlington, ON) with 2 mM L-glutamine
(Cat#25030-081, Invitrogen, Burlington, ON), 0.1 mM MEM nones-
sential amino acid solution (Cat#11140-050, Invitrogen, Burlington,
ON), 1000 U/ml ESGRO® (LIF) (Cat#ESG1107, Millipore/Chemicon,
Temecula, CA), and 16% Knockout™ Serum Replacement (Cat#10828-
028, Invitrogen, Burlington, ON)) (MEF media was replaced 3–5 h
prior to transfer). Blastocysts were cultured as per Cheng et al. [40]
with the following modiﬁcations: cells were cultured for 7–9 days in
KSR-ESC media with minimal disturbance (checked on day 2 to
determine if the blastocysts had ‘hatched’ out of the zona pellucida)
and no media changes. Blastocysts which hatched and had a well
developed ICM (inner cell mass) were treated with 20 μl 0.25%
trypsin-EDTA (Cat#25200-072, Invitrogen, Burlington, ON) for 5 min
at 37 °C, triturated with a 200 μl pipetman, inactivated with 30 μl
0.5 mg/ml soybean trypsin inhibitor (Cat#17075-029, Invitrogen,
Burlington, ON), and brought up to 200 μl with KSR-ESC media, then
transferred individually to a 24-well MEF plate containing 1800 μl
KSR-ESCmedia, for a total volume of 2 ml. Beginning 4 days later, KSR-
ESCmediawas replacedwith FBS-ESCmedia (DMEM (Cat#11960-069,
Invitrogen, Burlington, ON) with 2 mM L-glutamine (Cat#25030-081,
Invitrogen, Burlington, ON), 0.1 mM MEM nonessential amino acid
solution (Cat#11140-050, Invitrogen, Burlington, ON), 1000 U/ml
ESGRO® (LIF) (Cat#ESG1107, Millipore/Chemicon, Temecula, CA), 16%
ES Cell Qualiﬁed fetal bovine serum (FBS, Cat#16141-079, Invitrogen,
Burlington, ON), and 0.01% β-mercaptoethanol (Cat#M-7522, Sigma-
Aldrich, Oakville, ON)) in 25%, 50%, 75% proportions (respectively) to
adapt the cells to FBS containing media. On day 7 the cells were
trypsinized to one well of a 24-well plate containing 1 ml of 100% FBS-
ESC media, with daily media replacement. Once conﬂuent, wells
containing ESC colonies were expanded to 3×24-wells (with MEFs),
then passaged to 3×24- (with MEFs) and 3×12-wells (plastic — no
MEFs). Once conﬂuent, the 3×24-wells were combined, aliquoted
(3 vials), and frozen in ESC-freezemedia (50% FBS, 40% FBS-ESCmedia,
10% DMSO (Cat#D-2650, Sigma-Aldrich, Oakville, ON)), and the 3×12-
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Ottawa, ON), mixed and aliquoted for future DNA analysis. Cultures
were genotyped for X and Y Chromosomes [41], Gt(ROSA)
26Sortm1Sor and WT alleles (http://jaxmice.jax.org/pub-cgi/protocols/
protocols.sh?objtype=protocol&protocol_id=433, The Jackson Labora-
tory, Bar Harbor, ME), and Hprt1b-m3 and WT alleles as listed in Table 2.
B6129F1-Gt(ROSA)26Sortm1Sor/+, Hprt1b-m3/Y and B6129F1-Gt(ROSA)
26Sor+/+, Hprt1b-m3/Y cell lines were identiﬁed.
Knock-in at the Hprt1 locus
Plasmid DNA was puriﬁed with the Qiagen Maxi Kit (Cat#12163,
Qiagen, Mississauga, ON), resuspended in 10:1 Tris-EDTA (TE, pH7.0)
buffer, and linearized with I-SceI (Cat#R0694L, New England Biolabs,
Pickering, ON). Linearized plasmid DNAwas resuspended in 85 μl of TE
(10:0.1) to a ﬁnal concentration of 187.5 ng/μl. mEMS1204 ESCs were
grown to conﬂuence on 4–6 T75 ﬂasks of mitC treated Hprt1b-m3 MEFs
in FBS-ESC media. ESCs (1.7–2.5×107) in 720 μl 1×PBS were added to
the linearized DNA and electroporated in a Bio-Rad Genepulser using
a 4 mm electroporation cuvette (Cat#165-2081EDU, Bio-Rad, Mis-
sissauga, ON), at 240 V, 50 μF, 6–10 ms pulse, immediately
resuspended in a total volume of 5 ml of FBS-ESC media and plated
onto 5×100 mm dishes of mitC B6129F1WTMEFs in a total volume of
12 ml/100 mm dish. 24–36 h post-electroporation, correctly targeted
homologous recombinants were selected for using HAT media (FBS-
ESCmedia containing 1× HAT ((0.1 mM sodium hypoxanthine, 0.4mM
aminopterin, 0.16 mM thymidine), Cat#21060-017, Invitrogen, Bur-
lington, ON). HAT media was changed every day for the ﬁrst 3 days,
and then every 3rd day thereafter, for up to 10 days. Individual
colonies were counted and, typically, no more than 2 isolated colonies
were picked per 100 mm dish to optimize for independent homo-
logous recombination events. These colonies were expanded under
standard protocols for veriﬁcation of the desired recombination event.
Puriﬁcation and PCR analyses of genomic DNA
ESC clone DNAwas puriﬁed using the PromegaWizard SV Genomic
DNA Puriﬁcation System (Cat#PR-A2361, Fisher Scientiﬁc, Ottawa,
ON) with the following modiﬁcations: the ﬁnal elution volume varied
from 50 μl run through the column twice, or, 100 μl or 250 μl run
through once, resulting in approximately 100 ng/μl of sample DNA.
Tissue samples were digested overnight at 55 °C in 200 μl of tissue
homogenization buffer (THB) (50 mM KCl (Cat#BP366-500, Fisher
Scientiﬁc, Ottawa, ON), 10 mM Tris–HCl (pH 8.3) (Cat#PR-H5121,
Fisher Scientiﬁc, Ottawa, ON), 2 mM MgCl2 (Cat#BP214-500, Fisher
Scientiﬁc, Ottawa, ON), 0.1 mg/ml gelatin (Cat#G7-500, Fisher
Scientiﬁc, Ottawa, ON), 0.45% IGEPAL CA-630 (Cat#I8896-50ML,
Sigma-Aldrich, Oakville, ON), 0.45% Tween 20 (Cat#BP337-500, Fisher
Scientiﬁc, Ottawa, ON), autoclaved before use) with 120 μg/ml
Proteinase K (ProK, Cat#P2308, Sigma-Aldrich, Oakville, ON), followedTable 2
Genotyping assays and PCR primer sequences
Primer name Primer sequence (5′–3′) Assay
oEMS2240 GGCATCCAGTGCTCTTCACT Hprt1b-m3 allele, forward
oEMS2238 CCAGTGCTGACGTTACAAGC Hprt1 WT allele, forward
oEMS2236 TCCAGGGAATCCATCACAAT Hprt1 common primer, reverse
oEMS2502 TCAAAGGGGTGGATGACCG Tyrosinase ‘C’ (WT) allele, forward
oEMS2503 TCAAAGGGGTGGATGACCT Tyrosinase ‘c’ allele, forward
oEMS2509 CTCATCCCCAGTTAGTTCTCGAAT Tyrosinase common primer, reverse
oEMS2364 GCGTATCACGAGGCCCTTTC In vector, common primer, forward
oEMS2668 GCCAAGTAGGAAAGTCCCATAAGG Promoter-containing (CAG), reverse
oEMS2639 TGGCGGACTTGAAGAAGTCGT Promoterless (EGFP), reverse
oEMS2267 TCAGGCGAACCTCTCGGCTT HPRT1-CS (CS) allele, forward
oEMS2272 AGATGAGCTTGGTTGCTGGAGTG ‘WT @ CS’ allele, forward
oEMS2269 TGCTGGACATCCCTACTAACCCA CS common primer, reversewith 10 min at 95 °C to deactivate the ProK, and a brief spin to debris.
Each 25 μl PCR reaction contained: 200 ng DNA, 1 × PCR buffer
(Cat#18038-042, Invitrogen, Burlington, ON), 1.5 mM MgCl2
(Cat#18038-042, Invitrogen, Burlington, ON), 0.02 U/μl Taq Polymer-
ase (Cat#18038-042, Invitrogen, Burlington, ON), 0.2 mM dNTP mix
(Cat#10297-018, Invitrogen, Burlington, ON) and 0.5 μM both forward
and reverse primers. 5% dimethyl sulfoxide (DMSO, Cat#D-2650,
Sigma-Aldrich, Oakville, ON) was also added to the HPRT1-CS assay
PCRmix. All PCR assays in Table 2 used the following conditions: 94 °C
for 3 min, followed by 35 cycles: 94 °C for 1 min, 61 °C for 1 min, 72 °C
for 45 s, and a ﬁnal extension step at 72 °C for 5min. Samples were run
on a 2% agarose gel (1× TBE buffer) containing SYBR safe (2.5 μl/100ml
gel) (Cat#S33102, Invitrogen, Burlington, ON) under standard condi-
tions. Vector NTI (http://www.invitrogen.com) software was used to
design PCR assays for the different vector constructs. Table 2 lists all
primer sequences and PCR assays used for genotyping.
Derivation of knock-in mice
Chimeric mice from untargeted and targeted ESCs were generated
by microinjection [37] into B6 (E14TG2a-derived) and B6-Alb
(E14TG2a- and mEMS1204-derived) E3.5 blastocysts, or co-culture
[30] with diploid ICR E2.5morula (cultured overnight to the blastocyst
stage), followed by implantation into the uterine horns of 2.5 day
pseudopregnant ICR females. Chimeras were identiﬁed and coat color
chimerism determined as outlined below.
Male chimeras derived from the E14TG2a cell lines were mated
with B6 or B6-Alb females, and germline transmission was identiﬁed
in the former case by the transmission of the dominant Aw (white
bellied agouti) allele, making the progeny appear brownwith a cream
belly, or in the latter case by the combination of Aw and Tyrc-ch
(chinchilla), making the progeny appear golden. Non-germline
progeny from the cross to B6 were homozygous for the recessive a
(nonagouti) allele and appeared black, whereas non-germline
progeny from the cross to B6-Alb were homozygous for the recessive
Tyrc-2J (albino) allele and appeared white.
Male chimeras derived from the mEMS1204 cell lines were mated
with B6-Alb females, and germline transmission identiﬁed by the
presence of the dominant Tyr+ (tyrosinase wild type) and the Aw
(white bellied agouti) or a (nonagouti) alleles making the progeny
appear brownwith a cream belly or black, respectively. Non-germline
progeny were homozygous for the recessive Tyrc-2J (albino 2 Jackson)
allele and appearwhite. All germline female offspring should carry the
knock-in (KI) X Chromosome and were mated with B6 males. N2
offspring were analyzed for the presence of the KI allele by PCR.
Determination of coat color chimerism
E14TG2a- and mEMS1204-derived chimeras were identiﬁed and
level of coat color chimerism determined as follows. E14TG2a ESCs,
homozygous for Aw and Tyrc-ch, as they are derived from the 129/
OlaHsd strain [15], will produce chimeras with cream, chinchilla and
agouti patches on a black background when injected into B6
blastocysts. The cream patches result from melanocytes and dermis
derived solely from the ESCs (Aw/Aw, Tyrc-ch/Tyrc-ch), whereas chinch-
illa patches result from ESC-derived (Aw/Aw, Tyrc-ch/Tyrc-ch) melano-
cytes and host-derived (a/a, Tyr+/Tyr+) dermis. Agouti patches results
from the converse, host-derivedmelanocytes and ESC-derived dermis.
However, E14TG2a ESCs when injected into B6-Alb (a/a, Tyrc-2J/Tyrc-2J)
produce chimeras whose coats contain patches of cream and
chinchilla on a white background. The cream patches arise when the
melanocytes and dermis are derived primarily from the ESCs (Aw/Aw,
Tyrc-ch/Tyrc-ch), whereas the darker chinchilla areas arise from ESC-
derived melanocytes and a host-derived dermis.
mEMS1204-derived chimeras were identiﬁed and coat color
chimerism determined in the same manner. mEMS1204 ESCs,
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type) alleles will produce chimeras with agouti and black patches on a
white background when injected into B6-Alb blastocysts. The agouti
patches result when both the melanocytes and dermis are derived
solely from the ESCs (Aw/a, Tyr+/Tyr+), whereas black patches result
from ESC-derived melanocytes and host-derived (a/a, Tyrc-2J/Tyrc-2J)
dermis.
In order to rank score the chimeras and preferentially select for
chimeras derived from the highest possible ESC contribution, yet
recognizing that in some cases we would not be able to conclusively
identify which cell lineage contributed to the coat color determining
cells, overall chimerism was calculated by conservatively assigning
values to the various coat color patches, and summing them. For
E14TG2a cells injected into B6 hosts, cream areas were scored as 100%
ESC-derived, whereas chinchilla and agouti patches were scored as
50% ESC-derived, and in all cases black areas were scored as 0% ESC-
derived. mEMS1204 derived chimeras were scored in the same way
where agouti was 100%, black was 50%, and white was 0%, even
though white patches may have had some undetectable ESC-
contribution (in the dermis speciﬁcally). For E14TG2a injections into
B6-Alb, the cream and chinchilla patches derived on a white
background presented difﬁculty when attempting to estimate overall
coat color chimerism. As such, we estimated the percent chimerism
based solely on the total chimerism observed when compared to a
white mouse, resulting in slightly inﬂated overall percent chimerism
for this small cohort of mice.
Immunohistochemistry and immunoﬂuorescence
Micewere perfused with 4% paraformaldehyde (PFA) as previously
described [42]. Whole brains were dissected out and post-perfusion
immersion ﬁxed with PFA for 2–3 h at 4 °C. Brains were then
transferred to 20% sucrose at 4 °C overnight with gentle shaking. The
brains were cryostat sectioned sagittally at 12–14 μm andmounted on
superfrost-plus slides (Cat#12-550-15, ThermoFisher Scientiﬁc,
Waltham, MA). EGFP expression was detected by direct ﬂuorescence
using a BioRad laser scanning confocal microscope (CLSM, BioRad,
Hercules, CA). Equivalent ﬁelds from individual animals were
captured via CLSM using identical laser power and gain settings
(Figs. 5A, B), then laser intensity was reduced to 30% and gain
settings were decreased by 50–60% to capture the positive control
tissue without overexposure (Fig. 5C).
Statistical analyses
Statistics were performed using Chi-square test (Fig. 3A) and
Mann–Whitney U Test with Z adjustment (Fig. 3B). All analyses were
accomplished using the Statistica v6.0 program (Statsoft, Tulsa, OK).
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